Cash and cash equivalents (USD, thousands)

Marketable securities (USD, thousands)

Other current assets (USD, thousands)

Current assets of discontinued operations (USD, thousands)

Total current assets (USD, thousands)

Property and equipment, net (USD, thousands)

Operating lease right-of-use assets (USD, thousands)

Investments measured at fair value (USD, thousands)

Intangible assets, net (USD, thousands)

Other assets (USD, thousands)

Total assets (USD, thousands)

Accounts payable (USD, thousands)

Accrued expenses (USD, thousands)

Operating lease liabilities (current) (USD, thousands)

Current portion of long-term debt (USD, thousands)

Other current liabilities (USD, thousands)

Current liabilities of discontinued operations (USD, thousands)

Total current liabilities (USD, thousands)

Liability instruments measured at fair value (USD, thousands)

Operating lease liabilities, noncurrent (USD, thousands)

Long-term debt, net of current portion (USD, thousands)

Other liabilities (USD, thousands)

Total liabilities (USD, thousands)

Additional paid-in capital (USD, thousands)

Retained earnings (USD, thousands)

Accumulated other comprehensive income (loss) (USD, thousands)

Shareholders’ equity attributable to Roivant Sciences Ltd. (USD, thousands)

Noncontrolling interests (USD, thousands)

Total shareholders’ equity (USD, thousands)

Total liabilities and shareholders’ equity (USD, thousands)

2a67aaf72bb6234f9569f8a8ec959922420a51ba23102c325a68eea1c20f0683

Revenue, net [USD, thousands]

Product revenue, net [USD, thousands]

License, milestone and other revenue [USD, thousands]

Cost of revenues [USD, thousands]

Research and development expenses [USD, thousands]

Acquired in-process research and development expenses [USD, thousands]

Selling, general and administrative expenses [USD, thousands]

Total operating expenses [USD, thousands]

Gain on sale of Telavant net assets [USD, thousands]

Loss from operations [USD, thousands]

Change in fair value of investments [USD, thousands]

Change in fair value of debt and liability instruments [USD, thousands]

Gain on deconsolidation of subsidiaries [USD, thousands]

Interest income [USD, thousands]

Interest expense [USD, thousands]

Other expense (income), net [USD, thousands]

Income (loss) before income taxes [USD, thousands]

Income tax expense (benefit) [USD, thousands]

Income (loss) from continuing operations, net of tax [USD, thousands]

Income (loss) from discontinued operations, net of tax [USD, thousands]

Net income (loss) [USD, thousands]

Net loss attributable to noncontrolling interests [USD, thousands]

Net income (loss) attributable to Roivant Sciences Ltd. [USD, thousands]

5beb3e629197802ca58edc9f004ac1b66c56b0950d68da943917ec680ac8082a

Net income (loss) [Operating Activities] (USD, thousands)

Adjustments to reconcile Net income (loss) to Net cash used in operating activities: Share-based compensation (USD, thousands)

Adjustments to reconcile Net income (loss) to Net cash used in operating activities: Change in fair value of investments (USD, thousands)

Adjustments to reconcile Net income (loss) to Net cash used in operating activities: Change in fair value of debt and liability instruments (USD, thousands)

Adjustments to reconcile Net income (loss) to Net cash used in operating activities: Gain on deconsolidation of subsidiaries (USD, thousands)

Adjustments to reconcile Net income (loss) to Net cash used in operating activities: Gain on sale of Telavant net assets (USD, thousands)

Adjustments to reconcile Net income (loss) to Net cash used in operating activities: Depreciation and amortization (USD, thousands)

Adjustments to reconcile Net income (loss) to Net cash used in operating activities: Non-cash lease expense (USD, thousands)

Adjustments to reconcile Net income (loss) to Net cash used in operating activities: Other (USD, thousands)

Changes in assets and liabilities, net of effects from acquisition and divestiture: Other current assets (USD, thousands)

Changes in assets and liabilities, net of effects from acquisition and divestiture: Accounts payable (USD, thousands)

Changes in assets and liabilities, net of effects from acquisition and divestiture: Accrued expenses (USD, thousands)

Changes in assets and liabilities, net of effects from acquisition and divestiture: Operating lease liabilities (USD, thousands)

Changes in assets and liabilities, net of effects from acquisition and divestiture: Other (USD, thousands)

Net cash used in operating activities (USD, thousands)

Cash flows from investing activities: Purchase of property and equipment (USD, thousands)

Cash flows from investing activities: Proceeds from sale of subsidiary interests (USD, thousands)

Cash flows from investing activities: Proceeds from sale of Telavant net assets, net (USD, thousands)

Cash flows from investing activities: Cash decrease upon deconsolidation of subsidiaries (USD, thousands)

Cash flows from investing activities: Other (USD, thousands)

Net cash (used in) provided by investing activities (USD, thousands)

Cash flows from financing activities: Proceeds from issuance of the Company’s common shares, net of issuance costs paid (USD, thousands)

Cash flows from financing activities: Proceeds from issuance of subsidiary common shares, net of issuance costs paid (USD, thousands)

Cash flows from financing activities: Payment of subsidiary dividend (USD, thousands)

Cash flows from financing activities: Repayment of debt by subsidiary (USD, thousands)

Cash flows from financing activities: Payments on principal portion of finance lease obligations (USD, thousands)

Cash flows from financing activities: Proceeds from exercise of the Company’s and subsidiary stock options (USD, thousands)

Cash flows from financing activities: Taxes paid related to net settlement of equity awards (USD, thousands)

Cash flows from financing activities: Repurchase of common shares (USD, thousands)

Cash flows from financing activities: Proceeds from issuance of the Company’s common shares under employee stock purchase plan (USD, thousands)

Cash flows from financing activities: Proceeds from exercise of the Company’s warrants (USD, thousands)

Cash flows from financing activities: Payment for redemptions of the Company’s warrants (USD, thousands)

Net cash (used in) provided by financing activities (USD, thousands)

Effect of exchange rate changes on cash, cash equivalents, and restricted cash (USD, thousands)

ae5762954e13054b9edf0d41a7648a9e7c4c46e053f1849d565d9f9a00ad658e

Current Assets (USD, thousands)

Cash and Cash Equivalents (USD, thousands)

Accounts Receivable (USD, thousands)

Inventory (USD, thousands)

Non-Current Assets (USD, thousands)

Property, Plant, and Equipment (USD, thousands)

Goodwill (USD, thousands)

Intangible Assets (USD, thousands)

Current Liabilities (USD, thousands)

Accounts Payable (USD, thousands)

Short-term Debt (USD, thousands)

Accrued Expenses (USD, thousands)

Non-Current Liabilities (USD, thousands)

Long-term Debt (USD, thousands)

Lease Liabilities (USD, thousands)

Deferred Tax Liabilities (USD, thousands)

Shareholders' Equity (USD, thousands)

Retained Earnings (USD, thousands)

Common Stock (USD, thousands)

Additional Paid-in Capital (USD, thousands)

1cf75fccf000b42e4c1d38658e5a5e4a3e8e3cfa3b1c072eb29fd448f7c7f32f

Total Revenue (USD)

Cost of Goods Sold (COGS) (USD)

Selling, General, and Administrative Expenses (SG&A) (USD)

Research and Development (R&D) (USD)

Depreciation and Amortization (D&A) (USD)

Interest Expense (USD)

Operating Income (EBIT) (USD)

Net Income (USD)

Earnings Per Share (EPS) - Basic (USD)

Earnings Per Share (EPS) - Diluted (USD)

11e7824ad8d86e54b974584d69de8786476902186828acd82ac7ccb9547ee23f

Adjustments for Non-Cash Items (USD, thousands)

Stock-Based Compensation (USD, thousands)

Changes in Working Capital (USD, thousands)

Capital Expenditures (CapEx) (USD, thousands)

Proceeds from / Repayments of Debt (USD, thousands)

Share Repurchases (USD, thousands)

Dividend Payments (USD, thousands)

Net Change in Cash (USD, thousands)

2606c6c64c5522d8f794b9904e23343d94b6e7482af817e9ae0b2426c744993a

Roivant Sciences (ROIV)

Financials